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SUMMARY: Treatment of cultured adult human keratinocytes with platelet activating factor 
(PAF) resulted in a rapid, dose dependent accumulation of inositol phosphates. Inositol trisphos- 
phate (IP ), 
seconds o ! 
inositol bisphosphate (IP,) and inositol phosphate (IP) were elevated within 15 
exposure to PAF (1pM). Lyso-PAF, phosphatidylcholine (PC) and lyso-PC had no ef- 
feet on levels of inositol phosphates, indicating that the effect of PAF was specific. PAF also 
raised cellular 1,2-diacylglycerol content (a-fold) within two minutes of addition and stimulated 
mobilization of arachidonic acid (AA) and release of prostaglandin Es. In contrast, PAF did not 
stimulate phosphoinositide turnover or AA release in cultured dermal fibroblasts. These results 
suggest that the inflammatory effects of PAF in human skin result, at least in part, from its 
ability to directly activate keratinocytes and stimutate release of pro-inflammatory eicosanoids. 
0 1989 Academic Press, Inc. 
Platelet activating factor (PAF) is derived from 1-0-alkyl, 2-acyl phosphatidylcholine and 
is a potent mediator of platelet aggregation, bronchial constriction and inflammation. PAF is 
synthesized primarily by polymorphonuclear neutrophils, monocytes, platelets, macrophages and 
endothelial cells (for review see l-3). 
PAF exerts its effects on target cells through specific receptors coupled to 
phosphoinositide-specific phospholipase C (PLC). This reaction results in the formation of two 
intracellular second messengers, inositol 1,4$trisphosphate (IPs) and 1,2-diacylglycerol (DAG). 
IPs acts to raise intracellular calcium and DAG stimulates protein kinase C (PK-C). Elevated 
intracellular calcium and activated PK-C act synergistically to initiate a cascade of biochemical 
reactions that modulate cell function (for review see 4,5). 
Intradermal injection of PAF into human subjects elicits an inflammatory reaction in the 
skin characterized by erythemia and a perivascular mixed cellular infiltrate (6). Mallet et al. have 
reported increased levels of PAF in the skin of patients with psoriasis and have suggested that 
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PAF may be involved in the pathogenesis of this hyperplastic inflammatory skin disease (7). 
Keratinocytes are the predominant cell type in the epidermis and are capable of responding to, 
and synthesizing a variety of pro-proliferative and pro-inflammatory cytokines (interleukin- 1, 
interleukin-6, transforming growth factor-a, tumor necrosis factor and granulocyte/monocyte 
colony stimulating factor) and eicosanoids (PGE,, PGF, and 12-HETE) (8-13). Treatment of 
keratinocytes in vitro and skin in vivo with the PK-C activator 12-O-tetradecanoylphorbol-13- 
acetate (TPA) induces many of these mediators (lo-12), suggesting that their levels may be regu- 
lated in some manner by PK-C. This concept is further supported by the demonstration that the 
psoriasis-like inflammatory reaction of mouse skin to TPA is blocked by the PK-C inhibitor 
sphingosine (14). The ability of PAP to induce cutaneous inflammation thus raises the possibility 
that it may act to induce the release pro-inflammatory mediators from epidermal keratinocytes 
via direct activation of the PLC/PK-C signal transduction system. Alternatively, PAF may 
directly activate mediator release from fibroblasts within the dermis which then in turn may act 
on keratinocytes. To investigate this issue we have examined the ability of PAF to induce phos- 
phoinositide turnover and arachidonic acid mobilization in cultured adult human keratinocytes 
and dermal fibroblasts. 
MATERIALS AND METHODS 
Materials. [Y-~‘P]ATP, [SH]arachidonic acid, [sH]myo-inositol and prostaglandin Es 
radioimmunoassay assay kit were obtained from New England Nuclear (Boston, MA). Pertussls 
toxin was purchased from List Biochemicals (Campbell, CA). Platelet activating factor was ob- 
tained from Serdary Biochemicals, (London, Canada). Lyso-platelet activating factor, phos- 
phatidylcholine, phosphatidylserine and lyso-phosphatidylcholine were from Avanti Polar Lipids 
(Birmingham, AL). Dowex 1X-8 formate form was from BioRad Laboratories (Richmond, CA). 
Modified MCDB 153 keratinocyte growth media (KGM) and growth factor free keratinocyte 
basal media (KBM) were obtained from Clonetics, Inc. (San Diego, CA). 
Cell Culture, Keratome biopsies (0.2 mm depth) of human epidermis were obtained from adult 
volunteers. Epidermal cells were disaggregated by incubation at 37” for 30 minutes in 0.25% 
trypsin, 0.1% EDTA. Cells were plated at lo7 cells/T-75 flask in KGM (15). Cells were ex- 
panded by passage at 80% confluency and utilized between passage 2 and 6. Dermal fibroblasts 
were grown from dermal explants in McCoy’s 5A media containing 10% fetal calf serum. 
La ellin b f I’Hlinositol ohosohates, Keratinocytes and fibroblasts 
were seeded in 35mm dishes and allowed to grow to 70% confluency. Keratinocytes were 
labelled with [SH]myo-inositol (l@i/ml) in inositol free KBM for 48 hours. Fibroblasts were 
labelled similarly in Medium 199. The media was removed and cells were incubated in phosphate 
buffered saline containing 1OmM LiCl for 10 minutes prior to addition of agonist. Following 
stimulation, ice cold methanol/HCL (21:0.01) was added and the cells scraped from the dish. 
[3HJinositol phosphates were separated by Dowex ion exchange chromatography and quantified 
by liquid scintillation counting (16). 
Measurement of 1.2-diacvlnlvcerol, Cellular 1,2-diacylglycerol content was determined by the 
method of Preiss et al., utilizing E. Coli diacylglycerol kinase (17). 
. . . 
FO% cozfluentf inr 3~~m?lishes) wire labelledrwithlIsHl~ra&donic acid (0.5 rr(=i/ml) for 16 
( Keratinocytes and fibroblasts 
hours in KBM and Delbecco’s modified Eagles medium w&h 0.2% fetal calf serum, respectively. 
The cells were washed to remove unincorporated radioactivity and placed in 1 ml of media. At 
the indicated times following addition of agonist, 0.5 ml of media was removed, acidified and ex- 
tracted with an equal volume of ethylacetate. The ethylacetate extracts were dried in scintillation 
vials and counted. For measurement of prostaglandin Es, keratinocytes were grown in KGM con- 
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taining 1pM unlabelled arachidonic acid for 24 hours. Cells were washed with KBM to remove 
unincorporated arachidonic acid prior to stimulation with agonist for the indicated times. Pros- 
taglandin Es in the media was determined using a commercial radioimmunoassay kit. 
RESULTS AND DISCUSSION: Exposure of cultured adult human keratinocytes to PAF (1pM) 
resulted in rapid significant elevations in IPs, IPs and IP (figure 1). IP, was maximally elevated 
@-fold) within 15 seconds and remained above the initial level for at least 4 minutes, IP, in- 
creased over 1 minute and remained maximally elevated (&fold) for at least 4 minutes. IP in- 
creased steadily between 0 and 4 minutes to a level IO-fold above the initial value. Increased 
formation of inositol phosphates was detected at PAF concentrations between 10~‘“-10~6 M (data 
not shown). Half maximal stimulation ocurred at 5 X lo-‘M PAF. 
The effect of several different phospholipids on accumulation of inositol phosphates was 
examined. Phosphatidylcholine, lyso-phosphatidylcholine and phosphatidylserine at iO‘6M and 
lyso-PAF at IO-‘M were unable to simulate formation of inositol phosphates in human 
keratinocytes (data not shown). These data indicate that the ability of PAF to induce formation 
of inositol phosphates is specific. 
In a variety of cell types, agonist-induced phosphoinositide hydrolysis is inhibited by 
TPA and in some cases by pertussis toxin. Evidence indicates that these agents act to uncouple 
agonist receptors from phospholipase C by inhibition of an as yet unidentified GTP-binding 
protein(s) (Gx). Inhibition by TPA is believed to occur via protein kinase C-mediated uncou- 
pling of Gx from phospholipase C, while inhibition by pertussis toxin may occur via ADP- 
ribosylation of G, thereby uncoupling it from agonist receptors (18). In cultured adult human 
keratinocytes TPA caused significant inhibition of PAF-induced formation of inositol phosphates 
(figure 2). IP, IP,, and IP, were each inhibited 50% by TPA. Treatment with pertussis toxin also 
resulted in inhibition of PAF-induced formation of inositol phosphates although to a lesser 
degree (25%) than TPA (data not shown). Pertussis toxin has been reported to inhibit PAF- 
induced phosphoinositide turnover in neutrophils (19) and macrophages (20) but not to be in- 
hibitory in monocytic leukemic U-937 cells (21). Taken together the phospholipid specificity and 
sensitivity to TPA and pertussis toxin of PAF-induced formation of inositol phosphates are con- 
i.:...//-1/- ;:-fQ 
I For’” 0 153060 120 240 0 153060 120 240 0 153060 120 240 
0 
saoonda 
m Time course of PAF-induced formation of inositol phosphates in cultured adult human 
keratinocytes, Keratinocytes were labelled with [sH]myo-inositol (@Ci/ml) for 48 hours in in- 
ositol free KBM. [aH]inositol phosphates were extracted and analyzed by Dowex chromatography 
as described in “METHODS”. Data points are means f  SEM for triplicate dishes from three 
separate experiments. PAF concentration 1pM. 
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Fs Inhibition of PAF-induced formation of inositol phosphates by TPA. Experimental 
conditions were similar to those described in the legend to figure 1 with the exception that the 
keratinocytes were incubated with TPA (50nM) for 20 minutes prior to the addition of PAF 
(2/rM) for four minutes. 0 , PAF; q , TPA + PAF. Results are the means +SEM of triplicate 
dishes from two separate experiments. 
Finure 3, Time course of PAF-induced formation of 1,2-diacylglycerol (DAG) in cultured 
human keratinccytes. Keratinocytes (4.5X106/100mm dish) were treated with PAF (1pM) for the 
indicated times. At the termination of the incubation, media was aspirated and the cells were 
scraped from the dish in ice cold methanol. DAG was extracted and quantified as described in 
“METHODS”. Data points are the means of triplicate dishes from a representative xperiment. 
The experiment was repeated three times with similar results. 
sistent with PAF acting through specific receptors expressed on human keratinocytes coupled via 
a G-protein to phospholipase C. 
In addition to producing IP,, agonist-induced phosphoinositide turnover is associated with 
the production of a second intracellular messenger DAG. We therefore investigated the effects of 
PAF on DAG content in cultured keratinocytes. Addition of PAF caused a rapid transient in- 
crease in DAG content (figure 3). DAG was maximally stimulated (2-fold) within 1 minute and 
remained elevated for 5 minutes, after which it returned to the initial level. The slower kinetics 
of PAF-induced DAG formation compared to that of IP, (figure 1) suggest that phospholipid 
headgroup classes other than phosphoinositides may serve as sources for at least some portion of 
the elevated DAG, as has been observed in PAF-stimulated peritoneal macrophages (22). 
In addition to stimulating phosphoinositide turnover and DAG formation in human 
keratinocytes, PAF also elicited mobilization of arachidonic acid and prostaglandin Es synthesis. 
PAF-stimulated release of radioactivity from keratinocytes labelled with [‘Hlarachidonic acid was 
dose and time dependent. Arachidonic acid release was elevated within 5 minutes and continued 
to increase over 30 minutes (figure 4A). Release of radioactivity from [zH]arachidonic acid 
labelled keratinocytes was elevated 3-fold and prostaglandin Es release was elevated S-fold fol- 
lowing exposure of keratinocytes to PAF for 15 minutes (figure 4B). 
A recent report indicates that human dermal fibroblasts are capable of synthesizing PAF 
(23). Since cells that synthesize PAF often also respond to it, dermal fibroblasts, in addition to 
keratinocytes, may be targets for the actions of PAF in skin. To investigate this, we determined 
whether PAF was able to stimulate phosphoinositide turnover and/or arachidonic acid mobi- 
lization in cultured adult human dermal fibroblasts. PAF caused no detectable increases in IP, 
IPs, IP, or release of [SH]arachidonic acid metabolites. In contrast, bradykinin (BK), a known 
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Figure PAF-stimulated release of arachidonic acid and prostaglandin E in cultured human 
keratinocytes. A) Keratinocytes were labelled with [SH]arachidonic acr (05&i/ml) for 16 d
hours. Cells were stimulated with PAF (1pM) for the indicated times and the radioactivity in the 
media was extracted and counted as described in “METHODS”. B) Keratinocytes were grown in 
KGM supplemented with arachidonic acid (IpM) for 24 hours. Left panel: Experimental condi- 
tions similar to those in (A). Keratinocytes were treated with PAF (IpM) for 15 minutes. Right 
panel: Unlabelled cells were stimulated with PAF (1pM) for 15 minutes. Prostaglandin Es was 
quantified by RIA. Results are the means f SEM for triplicate dishes from three separate ex- 
periments. 
phospholipase C agonist in fibroblasts (24) significantly elevated inositol phosphates and release 
of arachidonic acid (Table I). The lack of responsiveness of cultured human dermal fibroblasts to 
PAF suggests that these cells may not express PAF receptors. 
The above data demonstrate that adult human keratinocytes, but not dermal fibroblasts, 
are direct targets for the actions of PAF. PAF activates both arms of the bifurcating PLC/PK-C 
signal transduction system in human keratinocytes, stimulating IP, and DAG formation. In addi- 
tion, PAF induces eicosanoid release. The activation of keratinocytes by PAF is likely to be an 
important mechanism through which PAF exerts its inflammatory effects in skin. Infiltration of 
polymorphonuclear leukocytes and macrophages, which synthesize PAF, is commonly observed in 
TABLE I 
Bradykinin but not PAF Stimulates Phosphoinositide Turnover 
and Arachidonic Acid Release in Human Dermal Fibroblasts 
I~lIlloritol Phosphates (cpm)’ 
Addition IP IPs IP8 AA Mctabdites (cpm)** 
None 
PAF 10-r 
5,113&43 5292 29 2,674dll 39&367 
IO-*M 
5.425&290 466~ 16 1,957& 79 2782&W 
2,512&123 3379&3 
IO-‘M 
5,103@32 475): 33 
5,441#280 4482 27 1,852& 45 3193h478 
BK lpM 47,51&792 3.910%227 6,44&405 79lW35 
Inositcl phosphates (IP, IPs end IP ) and arachidcnlc acid (AA) measured four and 30 minutes 
after addition of agonist, respective y. BK, bradykhrin; PAF, platelet activating factor. f 
* Values are means i SEM of quadruplicate dishes from a representative experiment repeeted 
three times. 
**Values are means f: SEM of triplicate dishes from a representative experiment repeated twice. 
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a variety of inflammatory skin diseases. Our data suggest hat the presence of PAF within the 
epidermis would lead to stimulation of protein kinase C and calcium/calmodulin regulated en- 
zymes within keratinocytes, resulting in elevated release of pro-inflammatory eicosanoids. PAF 
may also influence many other keratinocyte protein kinase C-mediated responses uch as cytokine 
release, growth and differentiation. 
We have previously demonstrated that inflammatory factors such as bradykinin, thrombin 
and histamine also stimulate phospholipase C-catalyzed phosphoinositide turnover and elevate 
DAG content in human keratinocytes (25). We therefore propose that the phospholipase 
C/protein kinase C signal transduction system in human keratinocytes is a key pathway through 
which mediators of skin inflammation act. This hypothesis predicts that receptor antagonists of 
PAF, bradykinin, histamine, and thrombin and inhibitors of phospholipase C and protein kinase 
C might be effective anti-inflammatory agents in skin. Investigations are in progress to address 
this issue. 
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